A serological survey on neutralizing antibody titer of SARS convalescent sera

A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Provi...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 77; no. 2; pp. 147 - 150
Main Authors Zhang, Jian-San, Chen, Jiang-Ting, Liu, Yu-Xuan, Zhang, Zhen-Shan, Gao, Hong, Liu, Yan, Wang, Xu, Ning, Ye, Liu, Yu-Fen, Gao, Qiang, Xu, Jian-Guo, Qin, Chuan, Dong, Xiao-Ping, Yin, Wei-Dong
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.2005
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.
Bibliography:ark:/67375/WNG-CTTG3L81-5
istex:F066BD559402A5F38564C58EA794B07017CF14D3
ArticleID:JMV20431
Research on Inactivated SARS Vaccine - No. 2003AA208201
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.20431